Lékař, který se nepostará sám o sebe, není zárukou dobré péče o pacienta

MUDr. Radkin Honzák CSc

Onkologie. 2009:3(5):271  

Karcinom plic - doba pomalých, ale optimistických proměn

prof. MUDr. Vítězslav Kolek DrSc

Onkologie. 2009:3(5):275-276  

Local therapy of lung cancer

Jiří Klein

Onkologie. 2009:3(5):277-280  

Local therapy such as surgery clearly plays an important role in the treatment of lung cancer. The decision to include surgery as a part of the treatment plan hinges on an understanding of the anticipated benefits as well as the associated risks.

The role of radiotherapy in lung cancer treatment

Milada Zemanová

Onkologie. 2009:3(5):281-284  

Radiotherapy plays a crucial role in the treatment of lung cancer, whether designed as part of a potentially curative treatment plan or intended as palliative therapy to suppress symptoms such as haemoptysis, dyspnoea due to bronchial obstruction, or chronic pain. Radiotherapy, with either curative or palliative intent, should be used for the treatment of up to 76 % of all patients at some stage of the disease, while, in the Czech Republic, only 20–24 % of lung cancer patients actually receive radiotherapy every year. Radiotherapy is particularly useful in locally advanced, inoperable stage, but with the recent technological advances allowing...

The role of chemotherapy in lung cancer treatment

doc. MUDr. Jana Skřičková CSc, Lenka Babičková, Jana Špeldová

Onkologie. 2009:3(5):285-291  

According to statistics of the year 2005 bronchogenic carcinoma is one of the tumours with the highest incidence and in men the most common cause of death of malignant tumours. In the time of diagnosis determination more than 50 % of patients have tumours in advanced stages, when local treatment is not possible. One of the basis medical possibilities of bronchogenic carcinoma treatment is chemotherapy, that we are deal with in our message.

Biological therapy of non-small cell lung carcinoma

prof. MUDr. Petr Zatloukal CSc

Onkologie. 2009:3(5):292-296  

With the advent of third-generation drugs in the 1990s, major advances were made in the treatment of non-small cell lung carcinoma; however, standard cytostatic therapy has not shown any further significant improvement in therapeutic outcomes and may well have reached its limits. Therefore, research is focused on drugs that specifically react with the cell signalling molecules, either of tumour cells directly or inhibit vessel formation in the tumour. In addition to a different mechanism of action, they differ from standard chemotherapy in the more favourable spectrum of adverse events. Erlotinib, gefitinib, and bevacizumab have been introduced...

Bronchogenic carcinoma and its prognostic and predictive factors

Miloš Pešek

Onkologie. 2009:3(5):299-302  

Bronchogenic carcinoma is one of the most common tumours and one with a very poor prognosis. Despite significant advances in diagnosis and treatment, therapeutic outcomes have improved only slowly. Gradually, the proportion of morphologically confirmed neoplasms has increased as has the proportion of oncological patients. Both prognostic and predictive factors are used in making decisions about the treatment of such morphologically, clinically as well as genetically heterogeneous group of disease. The authors present the data on these factors, with a focus on selecting chemotherapy and biologically targeted therapy. One of the predictors of chemotherapy...

Cetuximab and irinotecan in therapy of chemoresistent metastatic colorectal cancer

Ilona Kocáková, MUDr. Ivo Kocák Ph.D, Radim Němeček

Onkologie. 2009:3(5):303-307  

It is estimated that 50 % of colorectal cancer patients develop metastases and eventually die of the disease. Epidermal growth factor receptor is often overexpressed in colorectal cancer and is associated with increased tumor stage, worse histologic grade and lower survival rates. Cetuximab is a chimeric monoclonal antibody that binds to the epidermal growth factor receptor and thereby inhibits cell proliferation, metastasis and angiogenesis. Cetuximab improves tumor response when used in conjunction with chemotherapy in patients with metastatic colorectal cancer. Improved treatment efficacy may help to increase the rate of hepatic resection after...

Bisphosphonates in the lung cancer patients with bone metastases

MUDr. Gabriela Krákorová Ph.D

Onkologie. 2009:3(5):308-310  

Bone metastases in lung cancer are present in 30–60 % cases. Bone metastases are accompanied with the risk of skeletal related events (SRE), significantly decreasing survival and quality of life (mobility, pain, social independence). Zolendronic acid is the only one biphosphonate recommended for lung cancer patients with bone metastases. The panel of European experts 2009 suggests early screening of the bone metastases at the time of diagnosis to assess the symptomatic and reveal asymptomatic bone metastases (using PET or bone scan). Biphosphonate is recommended in the therapy of metastases to prevent the development of other metastases to...

Up-to-date experience with lenalidomide therapy in patients with multiple myeloma in the Czech Republic - pilot data in highly pretreated patients

Luděk Pour, prof. MUDr. Vlastimil Ščudla CSc, MUDr. Evžen Gregora, MUDr. Vladimír Maisnar Ph.D, MUDr. Miroslava Schützová, doc. MUDr. Ivan Špička, CSc, MUDr. Jaroslav Bačovský CSc, MUDr. Jan Straub, Roman Hájek

Onkologie. 2009:3(5):311-313  

Lenalidomide (Revlimid) belongs to immunomodulatory drugs called IMiDs, substances structurally relative to thalidomide. In patients with multiple myeloma (MM), this drug was shown to have a high efficacy in clinical trials both in primary therapy and in patients with relapse. Myelosuppression is a limiting toxicity in lenalidomide therapy; however, unlike thalidomide and bortezomib, lenalidomide causes no neuropathy. In the Czech Republic, lenalidomide has been used in relapsed patients outside clinical trials since 2008. This paper presents an analysis of the therapeutic efficacy and adverse effects in MM patients treated with lenalidomide in...

Colorectal cancer prevention

Iva Brabcová, Mgr. Monika Kyselová, Alena Machová

Onkologie. 2009:3(5):316-318  

The Czech Republic occupies the leading place in the worldwide statistics of colorectal cancer incidence. Annually, 8,000 new cases of colorectal cancer are detected in the Czech Republic and approximately 5,000 patients die from this disease every year (1). Preventing this disease plays a major role in eliminating the risk factors, early diagnosis, detection of recurrence, and avoiding the sequelae of progressive colorectal cancer. The article is a review study of primary, secondary, tertiary, and quaternary prevention of colorectal cancer.

Informační technologie - úskalí a pasti ? (1. díl)

Onkologie. 2009:3(5):319-321  

Autodidaktický test 5/09

Onkologie. 2009:3(5):322